Treating lupus symptoms to a clear goal
Part of Immune system & allergy, Skin clinical trials.
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of lupus (SLE), meeting standard criteria
- You are 18 years or older
- Your lupus is not fully in remission right now
- You can clearly speak and understand German
- You can sign a written consent form to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This study is trying to better understand lupus (SLE) by looking at different types of the disease. It may help doctors find more personalized treatments in the future.
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.